LOS ANGELES--(BUSINESS WIRE)--Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT. ...

Core Insights - Holzer & Holzer, LLC is investigating whether Corcept Therapeutics Incorporated complied with federal securities laws following the issuance of a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for relacorilant [1] - The announcement led to a decline in Corcept's stock price, indicating potential investor concerns about the company's regulatory challenges [1] Company Overview - Corcept Therapeutics is focused on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company is publicly traded on NASDAQ under the ticker symbol CORT [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.What Happened?On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercorti ...

Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Corcept Therapeutics Inc. (NASDAQ: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/cort.What is this all about?Shares of Corcept Therapeutics fell more than 50% on December 31, 2025, after the Company disclosed ...

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on discovering, developing, and commercializing drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant, indicating that the FDA could not determine a favorable benefit-risk assessment without additional evidence of effectiveness from Corcept [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on December 31, 2025 [3].

Group 1 - Block & Leviton is investigating Corcept Therapeutics Inc. for potential securities law violations following a significant drop in share price [1][2] - Corcept Therapeutics' shares fell over 50% on December 31, 2025, after the company received a Complete Response Letter from the FDA regarding relacorilant, indicating the need for additional evidence of effectiveness [2] - Investors who purchased Corcept Therapeutics common stock and experienced a loss may be eligible to participate in the investigation [3] Group 2 - Block & Leviton is assessing whether Corcept Therapeutics committed securities law violations and may file an action to recover losses for affected investors [4] - The firm encourages investors who have lost money to contact them for further information and assistance [5] - Whistleblowers with non-public information about Corcept Therapeutics are invited to assist in the investigation, with potential rewards for information leading to successful recovery [6] Group 3 - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7]

Core Insights - Corcept Therapeutics is a mid-cap biotechnology company focused on therapies for severe endocrine and oncologic conditions, leveraging cortisol modulation to meet unmet medical needs with a growing portfolio of proprietary drug candidates [1] - The company generates revenue primarily from Korlym, an FDA-approved therapy for Cushing's syndrome, and is advancing a pipeline of selective cortisol modulators targeting various disorders [2] Transaction Details - William Guyer, the chief development officer, exercised 20,000 stock options and sold the resulting shares for approximately $703,656, which reflects a significant transaction involving direct common stock holdings [4] - Following this transaction, Guyer's direct common stock holdings decreased from 21,235 shares to 1,235 shares, a reduction of 94.18%, although he retains stock options for 250,000 shares [3] Financial Performance - Corcept reported third-quarter revenue of $207.6 million, an increase from $182.5 million year-over-year, driven by growth in Korlym prescriptions [6] - The company reaffirmed its full-year revenue guidance of $800 million to $850 million and ended the quarter with $524 million in cash and investments, indicating strong balance sheet flexibility [6] Market Context - The stock experienced a sharp decline on December 31 following an FDA complete response letter for relacorilant; however, the transaction by Guyer is viewed as a portfolio management decision rather than a shift in long-term outlook [5][7] - The core business remains strong despite regulatory setbacks, with the focus on clinical execution and the future of relacorilant being more critical than the recent stock transaction [7]

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP ("Scott+Scott†), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Scott+Scott is an ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2, Canaccord Genuity cut its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $140 to $99 but kept its Buy rating on the stock. This adjustment comes after the company reported that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Corcept stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...